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Abstract 
Background: Uterine aspirates are used in the diagnostic process of endometrial disorders, yet further applications 
could emerge if its complex milieu was simplified. Exosome‑like vesicles isolated from uterine aspirates could become 
an attractive source of biomarkers, but there is a need to standardize isolation protocols. The objective of the study 
was to determine whether exosome‑like vesicles exist in the fluid fraction of uterine aspirates and to compare proto‑
cols for their isolation, characterization, and analysis.
Methods: We collected uterine aspirates from 39 pre‑menopausal women suffering from benign gynecological dis‑
eases. The fluid fraction of 27 of those aspirates were pooled and split into equal volumes to evaluate three differential 
centrifugation‑based procedures: (1) a standard protocol, (2) a filtration protocol, and (3) a sucrose cushion protocol. 
Characterization of isolated vesicles was assessed by electron microscopy, nanoparticle tracking analysis and immu‑
noblot. Specifically for RNA material, we evaluate the effect of sonication and RNase A treatment at different steps of 
the protocol. We finally confirmed the efficiency of the selected methods in non‑pooled samples.
Results: All protocols were useful to isolate exosome‑like vesicles. However, the Standard procedure was the best 
performing protocol to isolate exosome‑like vesicles from uterine aspirates: nanoparticle tracking analysis revealed 
a higher concentration of vesicles with a mode of 135 ± 5 nm, and immunoblot showed a higher expression of 
exosome‑related markers (CD9, CD63, and CD81) thus verifying an enrichment in this type of vesicles. RNA contained 
in exosome‑like vesicles was successfully extracted with no sonication treatment and exogenous nucleic acids diges‑
tion with RNaseA, allowing the analysis of the specific inner cargo by Real‑Time qPCR.
Conclusion: We confirmed the existence of exosome‑like vesicles in the fluid fraction of uterine aspirates. They were 
successfully isolated by differential centrifugation giving sufficient proteomic and transcriptomic material for further 
analyses. The Standard protocol was the best performing procedure since the other two tested protocols did not 
ameliorate neither yield nor purity of exosome‑like vesicles. This study contributes to establishing the basis for future 
comparative studies to foster the field of biomarker research in gynecology.
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Background
Uterine aspirates (UAs), which are endometrial biopsies 
obtained by aspiration, are considered a very complex 
biological sample that highly represents the uterine cav-
ity milieu. It combines the components of the uterine 
fluid (secretions from the luminal epithelium and glands, 
proteins selectively transferred from blood, and likely 
contributors from tubal fluid) with a cellular fraction 
(endometrial and blood cells) [1]. Thanks to its location 
and composition, UAs reflect cytological and molecular 
alterations present in tissues from the female genital tract 
[2, 3]. Therefore, this sample is currently used for histo-
pathological examination, performed after the transvagi-
nal ultrasonography, to diagnose endometrial disorders 
[4, 5]. Biomedical research on UAs is limited. However, 
although few molecular studies have been performed, 
those have significantly contributed to improving sensi-
tivity and negative predictive value of UAs as a diagnostic 
tool for endometrial cancer [2, 3, 6]. To expand research 
in the field of biomarker discovery for gynecological 
pathologies using UAs, exosome-like vesicles (EVs) arise 
as a promising source of biomarkers.
EVs are 20–200  nm round membrane vesicles [7–9] 
released by multivesicular bodies fusing with the cell mem-
brane [10, 11]. These lipid bilayer entities bear well-pro-
tected proteins, lipids, and RNAs, mediating intercellular 
communication between different cell types [12–15]. Spe-
cific sorted information is horizontally transferred from the 
cells of origin to other cells, influencing the recipient cell 
functions [16]. EVs are constantly released by cells in cir-
culation or proximal body fluids, and therefore, they have 
been described in blood [17], urine [18], saliva, and breast 
milk [19], among other body fluids. Differently, microvesi-
cles (MVs) are 100–1000 nm vesicles originated by budding/
shedding of the plasma membrane [20]; their size range 
overlaps partially with that of EVs, hence hindering a com-
plete size-discrimination between these two populations 
of extracellular vesicles [21, 22]. The features of EVs have 
fostered biomarker research in many diseases [16, 23–25]. 
However, a major bottleneck when performing EVs-based 
studies is the lack of standardization for already challenging 
techniques to isolate and characterize EVs. Since EVs reflect 
the status of the originating cell [23], we propose the UAs’ 
fluid fraction as a promising source of EVs to find molecules 
that could improve the diagnosis, prognosis, and treatment 
of gynecological alterations. Here, we aim to determine 
whether EVs exist in UAs and to compare protocols for their 
isolation, characterization, and further RNA analysis.
Methods
Sample collection and processing
A total of 39 pre-menopausal patients with benign 
gynecological diseases or healthy donors who came to 
the Unit of Gynecology at Vall Hebron University Hospi-
tal were recruited following the ethically approved proto-
col for this study (approval number: PR_AMI_50-2012). 
All patients signed the informed consent. A descrip-
tion of the clinic-pathological features of all participat-
ing patients is detailed in Additional file 1: Table S1. An 
inclusion criterion was pre-menopause. Women who had 
been treated previously for gynecological pelvic cancer, 
as well as patients positive for the human immunodefi-
ciency virus and/or the hepatitis virus were excluded.
UAs were obtained by aspiration with a Cornier Pipelle 
(Gynetics Medical Products). Samples were placed in 
1.5 mL tubes and kept on ice through all the processing 
which included addition of phosphate buffered saline 
(PBS) in a 1:1 ratio (v/v), gently pipetting of the sam-
ple and centrifugation at 2500g (4  °C) in a F45-30-11 
rotor (Eppendorf Microcentrifuge 5417R) for 20  min to 
remove the cellular fraction. The remaining fluid fraction 
of the UA, from now on referred to as Supernatant (SN) 
fraction, was then aliquoted and frozen at −80  °C until 
needed. To compare isolation protocols, a pool of 27 SNs 
(samples 1–27; Additional file  1: Table  S1) were mixed 
and divided into 20 aliquots containing 445 µL.
Isolation of EVs
Protocols described in sections “I”, “II”, and “III” (Fig. 1a) 
were performed in quadruplicates to optimize EVs 
isolation. To optimize miRNA/mRNA extraction, 
modifications of the Standard protocol were tested in 
duplicates—section “IV” (Fig. 3a).
Standard protocol
EVs were obtained from the SNs of UAs by differential 
centrifugation, following a modification of a previously 
described EVs isolation protocol by Thery et  al. [26]. 
Briefly, SNs were thawed and diluted in PBS to a final vol-
ume of 25 mL. A centrifugation step at 10,000g (4 °C) for 
30  min was performed on a Thermo Scientific Heraeus 
MultifugeX3R Centrifuge (FiberLite rotor F15-8x-50c) to 
remove cell debris, macroparticles and apoptotic bodies. 
The resulting pellet enriched in MVs was resuspended in 
50 µL of PBS and frozen at −80 °C. Then, the supernatant 
was transferred to ultracentrifuge tubes (Beckman Coul-
ter) and filled with PBS to perform a first ultracentrifuga-
tion step at 100,000g (4 °C) for 2 h on a Thermo Scientific 
Sorvall WX UltraSeries Centrifuge with an AH-629 rotor. 
The supernatant of this second centrifugation was the 
soluble fraction and was frozen at −80 °C. This first pel-
let was resuspended in PBS and again centrifuged at 
100,000g (4  °C) for 1 h. The final pellet enriched in EVs 
(possibly along with MVs and some remaining apoptotic 
bodies) was resuspended in 50 µL of PBS. Five microliters 
from MVs and EVs pellets were reserved at −80  °C for 
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Fig. 1 Optimization of EVs isolation from uterine aspirates. a Schematic representation of the three protocols of EVs isolation, namely Standard 
(St), Filtration (F), and Sucrose (S) protocols. b Electron microscopy images of negatively stained EVs and MVs. c Size distribution of isolated EVs 
measured by NTA. d EVs concentration measured by NTA. e Immunoblot of isolated MVs, EVs and SF proteins (done in triplicates) against EVs/MVs 
markers and Haptoglobin. f Relative tetraspanins expression of EVs. The average of tetraspanins (CD9, CD63 and CD81) expression of each protocol 
was normalized to the Standard in order to have a relative measurement of EVs purity
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particle size distribution and quantification by nanopar-
ticle tracking analysis (NTA) while the rest of the sample 
was frozen at −80 °C for protein extraction.
Filtration protocol
The Filtration protocol consisted in depleting the super-
natant obtained after the 10,000g centrifugation of struc-
tures bigger than 200 nm using a sterile filter (Corning). 
The rest of the protocol remains the same as for the 
Standard.
Sucrose cushion protocol
A 30  % sucrose cushion (20  mM Tris–HCl,  pH  7.4 
in D2O)—density from 1.13–1.19 g/mL—was introduced 
to the Standard protocol following the first ultracentrifu-
gation at 100,000g. The sucrose cushion was then centri-
fuged for 1 h at 100,000g (4  °C). EVs were recovered by 
poling the tube with a needle and were then washed with 
PBS for 1 h at 100,000g (4 °C). The final pellet was resus-
pended in 50 μL of PBS and the same fractions as in Sec-
tion “I” were stored at −80 °C.
Experimental conditions for RNA extraction
Four experimental conditions (“A”, “B”, “C” and “D”) 
derived from the Standard protocol were tested, includ-
ing sonication and RNase A treatment at different points, 
as shown in Fig. 3a. EVs were sonicated five cycles of 5 s 
at 100 Amplitude (Sartorius). For RNase A treatment, 
EVs were incubated with 500 µL of 0.1 mg/mL RNase A 
(Qiagen) for 1 h at 37 °C.
Particle size distribution and quantification
NTA was performed using a NanoSight LM10 system 
(Malvern Instruments) equipped with a 405 nm laser and 
a Hamamatsu C11440 ORCA-Flash2.8 camera (Hama-
matsu). Data was analyzed with the NTA software 2.3. 
Size and concentration of particles were determined by 
the following settings: camera level and detection thresh-
old were set to maximum (15 or 16) and minimum (3–5), 
respectively; camera gain was set to 512; blur, mini-
mum track length, and minimum expected size were set 
to “auto.” Readings were taken in triplicates during 60  s 
at 18.87 frames/s, at room temperature ranging from 
23–25 °C.
Electron microscopy
Isolated MVs and EVs were analyzed per duplicate by 
transmission electron microscopy (TEM). Vesicles were 
fixed in 50 µL of 4 % paraformaldehyde. Gold grids were 
incubated with samples for 1 min. After removing sam-
ple excess, negative staining was performed by incuba-
tion with uranyl acetate for 1  min. After washing, grids 
were dried overnight at room temperature. Samples were 
observed with a transmission electron microscope JEOL 
1010 coupled to an Orius CCD camera (Gatan, Inc.), 
working at 80 kV with a tungsten filament.
Protein extraction
Protein extraction of EVs and MVs was performed by 
adding RIPA buffer (40  mM Tris pH 8, 300  mM NaCl, 
10  mM EDTA, 2  %Triton X-100, 1:100 protease inhibi-
tors (#P8340 Sigma-Aldrich) in 1:1 ratio (v/v) to isolated 
vesicles and incubating at −20 °C overnight. Lysates were 
thawed on ice and sonicated five cycles of 5  s at ampli-
tude 100 (Labsonic M, Sartorius Stedim Biotech) to 
ensure membrane disruption. Protein extraction of the 
soluble fraction collected after the 2 h ultracentrifugation 
step was performed by precipitation with 100  % stock 
solution of acetonitrile at a ratio of 1:5 (v/v) after incuba-
tion at −20 °C overnight, and sequential centrifugations 
at 14,000×g 4 °C for 30 and 15 min, respectively. Finally, 
the pellet was dried and resuspended in 500 µL of RIPA. 
Protein concentration was determined by Bio-Rad DC 
Protein Assay (Bio-Rad Laboratories) following manufac-
turer’s recommendations.
Immunoblot
Proteins were separated by 10  % SDS-PAGE and trans-
ferred to PVDF membranes. For blocking, membranes 
were soaked in 5 % non-fat dried milk in TBS-Tween20 
(0.01  %). Proteins were immunodetected using primary 
antibodies. Then the membranes were washed and incu-
bated with a secondary HRP-coupled antibody. Finally, 
HRP signal was revealed using the Immobilon Western 
Chemiluminescent HRP Substrate (ref. WBKLS0100; 
Merck Millipore). The intensity of the bands was densito-
metrically quantified using the Image J software (v. 1.45s).
Primary antibodies: mouse anti-CD9 (1:250; ref. 
555370, BD Biosciences), mouse anti-CD63 (1:1000; ref. 
OP171, Calbiochem), mouse anti-CD81 (1:1000; ref. 
sc-166028, Santa Cruz), mouse anti-TSG101 (1:500; ref. 
Ab83, Abcam), mouse anti-Flotillin-1 (1:250; ref. 610821, 
BD Biosciences), rabbit anti-Annexin V (1:1000; ref. 
ab108321, Abcam) and mouse anti-Haptoglobin (1:1000; 
ref. ab13429, Abcam). Secondary antibodies: rabbit anti-
mouse Immunoglobulins/HRP, 1:2000, ref. P0260, Dako; 
and goat anti-rabbit Immunoglobulins/HRP, 1:2000, ref. 
P0448, Dako. Bands’ intensity was quantified using the 
Image J software (v. 1.45s).
Total RNA extraction
Total RNA, including miRNAs and other RNAs, was 
isolated using Qiazol and miRNeasy MiniKit (Qiagen) 
according to manufacturers’ protocol. DNase I treatment 
(Qiagen) was used. RNA from EVs and MVs was eluted 
with 20 µL of Nuclease-free water (Ambion) and stored at 
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−80 °C until further analysis. In all RNA extractions per-
formed, 25 nmol of synthetic nonhuman miRNA-39 from 
Caenorhabditis elegans (cel-mir-39, 5′-UCACCGGGUG 
UAAAUCAGCUUG-3′) was added to each Qiazol lysate 
as a spike-in control for normalization in quantitative 
Real-Time qPCR (RT-qPCR) analysis [27–29]. RNA con-
centration and integrity were determined by capillary 
electrophoresis using the Agilent RNA6000PicoKit on an 
Agilent2100 Bioanalyzer (AgilentTechnologies).
Reverse transcription, pre‑amplification, and RT‑qPCR
For mRNA analysis, RNA was converted to cDNA 
using SuperScript III Reverse Transcriptase (Invitro-
gen). For miRNA analysis, RNA was reverse-transcribed 
using TaqMan MicroRNA Reverse Transcription Kit 
and miRNA-specific stem-loop primers. All cDNA 
was pre-amplified with TaqMan Preamp Master Mix 
Kit (Applied Biosystems) according to manufacturer’s 
instructions.
RT-qPCR was performed using TaqMan Universal 
MasterMix II, with UNG on an ABI7900 Real-Time PCR 
Systems with TaqMan probes against specific transcripts 
and miRNAs. Reactions were performed in triplicate, and 
only results with a standard deviation value  <0.37 were 
accepted. Data analysis was done with Expression Suite 
Software v1.0; the same baseline and threshold were set 
for each plate to generate threshold cycle (Ct) values for 
all the targets in each sample. Threshold levels were set 
into the exponential phase of the RT-qPCR. Synthetic 
cel-mir-39 was used for data normalization since the 
same amount of the oligonucleotide was added to each 
sample before the addition of the lysis reagent for RNA 
isolation.
Real‑Time qPCR TaqMan probes
All probes were purchased from LifeTechnologies. TSG101 
(Hs00173072), PDCD6IP-ALIX (Hs00183813_m1), CD24 
(Hs02379687), MUC16-CA-125 (Hs01065189), MUC1 
(Cf02626759_m1), 18S (4319413E), β-Actin (4333762T), 
GAPDH (Hs99999905_m1), miR-200b (002251), miR-
200c (002300), miR-223 (002295), miR-141 (000463), 
miR-205 (000509), miR-17 (002308), miR-106a (002169), 
RNU48 (001006), RNU6B (001093), RNU44 (001094), U75 
(001219), and miR-39 (000200).
Statistical analyses
Statistical analyses were performed using GraphPad 
Prism 5 software. The Student’s t test was applied to 
compare means of EVs concentration, particle size dis-
tribution, and expression of tetraspanins and miRNAs. 
The Pearsons’ Rho test was used to analyze correlation. 
The probability of p  <  0.05 was considered statistically 
significant.
Results
EVs are present in the fluid fraction of uterine aspirates 
and can be isolated by differential centrifugation‑based 
protocols
A pool of 27 UAs’ fluid fractions was used to compare 
three EVs isolation protocols based on differential cen-
trifugation—Standard, Filtration and Sucrose. In addition 
to EVs, we collected fractions corresponding to MVs and 
proteins from the soluble fraction to monitor differences 
in the enrichment in EVs. A schematic representation of 
the experimental work is depicted in Fig. 1a.
All three protocols permitted the isolation of EVs of 
the expected round cup shape [30], as observed by TEM 
(Fig.  1b). Both EVs and MVs appeared as well-defined 
bilayer vesicles but notably, the size of all EVs was smaller 
than that for MVs, especially in the case of Standard pro-
tocol. To further investigate EVs concentration and size 
distribution, samples were analyzed by NTA (Fig.  1c, 
d). The population of EVs isolated by the Standard and 
Filtration protocols followed a uniform size distribu-
tion with a unique peak corresponding to a mode of 
135 ±  5 and 115 ±  3  nm, respectively. For the Sucrose 
protocol, the distribution was not uniform; the mode was 
135  ±  42  nm but presented an additional peak around 
300  nm, and a high standard deviation was observed 
indicating less reproducibility of this isolation protocol. 
Differently, all MVs preparations presented a heterogene-
ous distribution, and a lower concentration than that for 
EVs (Additional file 2: Figure S1).
A reduction in EVs concentration was seen as more 
steps were added to the isolation protocol; signifi-
cant differences were observed between Standard and 
Sucrose protocols (p  =  0.029), and the same tendency 
was observed when comparing the Standard and Filtra-
tion protocols (Fig.  1d). To evaluate the purity of EVs 
obtained from each isolation protocol, we performed 
an immunoblot loading equal amounts of protein, and 
demonstrated that the expression of the tetraspanins 
CD63, CD9, and CD81—all considered late endosomal 
markers enriched in EVs [22, 31, 32]—was significantly 
higher in the Standard compared to the Sucrose protocol 
(p = 0.001) (Fig. 1e, f ). The same tendency was observed 
for TSG101, a known endosomal origin marker [33], 
and Flotillin-1, an element of the membrane lipid rafts 
[34, 35]. These two markers were practically undetect-
able in MVs preparations, indicating a different biogen-
esis of these vesicles. As expected, Annexin V, a marker 
of MVs [36], was highly expressed in all MVs prepara-
tions; however, it was also detected in EVs derived from 
the Standard protocol suggesting that the smallest MVs 
populations might have precipitated at 100,000g or that 
specificity of this marker is arguably. None of the MVs 
or EVs markers were detected in the soluble fraction, but 
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haptoglobin—an abundant protein found in blood—was 
highly expressed (Fig. 1e).
Altogether, we demonstrated that all protocols were 
able to enrich the sample in EVs. Nevertheless, we 
selected the Standard protocol for further applications 
since it allowed to obtain a higher EVs concentration, 
while maintained higher EVs-related markers and better 
reproducibility than the other tested protocols.
To confirm that the enrichment in EVs following the 
Standard protocol holds when analyzing individual sam-
ples, we recovered EVs, MVs and soluble proteins from 
the fluid fraction of 6 non-pooled UAs (samples 28–33, 
Additional file 1: Table S1). Concomitant to our previous 
observations in the pooled analysis, we observed that all 
EVs preparations from individual UAs had a similar size 
distribution, presenting a mode of 120–160 nm (Fig. 2a). 
The particles concentration differed clearly between 
patients but a total number of isolated EVs significantly 
correlated with the initial volume of UAs fluid fraction 
(r = 0.90, p = 0.02) (Fig. 2b, c), but not with protein con-
centration (Additional file  3: Figure  S2). On the other 
hand, no correlation was observed between a number 
of MVs and sample volume (Additional file 4: Figure S3). 
EVs markers were expressed in both EVs and MVs prep-
arations from all patients (Fig.  2d, e). As seen previ-
ously, tetraspanins expression was higher in EVs than in 
MVs, indicating that we isolated a population of vesicles 
enriched in EVs. Altogether, these results indicate that 
the Standard protocol is suitable to obtain EVs from indi-
vidual UAs.
Optimization of EVs isolation protocols for RNA analysis
To further optimize the Standard protocol to extract RNA 
specifically contained in EVs, we evaluated the effect 
of sonication and RNase treatment, which enhances 
membrane disruption and promotes RNA release, and 
degrades RNA material, respectively (Fig.  3a). Concen-
tration and quality of extracted RNA was determined by 
Bioanalyzer and RT-qPCR amplification of a set of miR-
NAs (miR-200b, miR-200c, miR-223, miR-17 and miR-
106a), which were selected based on their expression in 
the female genital tract and their reported existence in 
EVs [22, 37–40]. Protocol “A”, which includes sonication 
before RNase A treatment, was used as negative con-
trol. This condition confirmed the successful breakage 
of EVs due to sonication and the successful degradation 
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of RNA due to RNase A treatment, not obtaining RNA 
content nor amplification of any of the tested miRNAs 
(Fig. 3b, c). Protocols “B” and “D” did not deplete exter-
nal RNA since RNase A was not applied; both protocols 
resulted in small size RNA profiles, yielding the highest 
amount of total RNA (Fig. 3b) and the highest expression 
of miRNAs (Fig.  3c). Importantly, the introduction of a 
sonication step did not report any advantage to enhance 
the release of EVs RNA content; conversely, we observed 
smaller RNA fragments, which are susceptible of RNA 
damage. In protocol “C”, RNase A was able to degrade 
52 and 66  % of total RNA from treatment “B” and “D” 
respectively, suggesting that RNase A treatment is nec-
essary to clean up the external nucleic acids that bind to 
EVs surface. This protocol (no sonication but RNase A 
treatment) was selected as the most appropriate to ana-
lyze RNA specifically contained within EVs.
Next, we confirmed the efficiency of the selected proto-
col for RNA analysis in 6 additional non-pooled samples 
(Samples 34–39; Additional file 1: Table S1). Isolated EVs 
were similar in size, presenting a mode of 120–170  nm 
and contained RNA fragments from 25–300 nucleotides 
(Additional file 5: Figure S4). RNA concentration ranged 
from 108–851 pg/µL (Fig. 4a), which was sufficient to per-
form expression analysis by RT-qPCR. Sample volume, 
the total number of EVs and RNA concentration signifi-
cantly correlated (Additional file 6: Figure S5A–C). Before 
RNA extraction, we added cel-miR-39 as a spike-in con-
trol for data normalization purposes. As seen in Fig. 4b, 
its expression did not vary across different samples, 
indicating similar RNA extraction efficiency. Afterward, 
we tested the amplification of a set of 11 miRNAs and 8 
mRNAs by RT-qPCR, all of them previously reported in 
EVs [41, 42] (Fig. 4c). Delta Ct (dCt) values were relativ-
ized to the cel-miR-39 expression in each sample. We 
observed that 18S RNA presented the highest expression. 
Alix, TSG101, GAPDH and β-actin, EVs-related mark-
ers, along with MUC16 [43] and CD24 [44–46], proteins 
related to some gynecological alterations, were detected 
at RNA level. In addition to those tested for the optimiza-
tion, we also analyzed the expression of other female geni-
tal tract-related miRNAs [38], miR-141 and miR-205, plus 
a set of tissue endogenous miRNAs [47], RNU6B, RNU48, 
RNU44, and U75. Expression of miR-200b, miR-200c, 
miR-223, miR-17, and miR-106a was higher compared 
to miR-205 and miR-141. Interestingly, RNU6B, RNU48, 
RNU44, and U75 were expressed at very low level in EVs. 
Detection of female genital tract associated RNA in EVs 
from UAs supported the idea that EVs cargo might reflect 
the cell status and/or its origin. However, this study was 
designed to confirm the appropriate extraction of RNA 
material to pursue further RNA analysis on EVs isolated 
from UAs, and is not intended to draw any disease-spe-
cific conclusion.
Discussion
Here, we demonstrated that EVs exist in the fluid fraction 
of UAs by comparing three protocols of isolation, all of 
them based on ultracentrifugation, as this has been the 
method of choice for concentrating and isolating EVs 
in several body fluids [48]. Moreover, we carried out an 
extensive characterization describing their morphol-
ogy, size and enrichment in well-known EV markers. 
When comparing the Standard, Filtration, and Sucrose 
protocols, we observed that all of them were capable of 
isolating EVs; but in particular, the Standard protocol 
permitted not only a higher recovery of EVs, but also a 
higher enrichment in tetraspanins. Furthermore, this 
protocol was the simplest, most reproducible and less 
costly protocol investigated here.
Many studies did not consider whether identified RNAs 
were contained in EVs or adhered externally to their outer 
membrane and, consequently, co-precipitated with EVs 
during the isolation protocol [49–51]. Here, we also estab-
lished the optimal conditions to extract EVs RNA content 
treating isolated vesicles with RNase A and not applying 
sonication. Even though sonication was applied to suc-
cessfully disrupt EVs membrane to improve protein yield 
[52], when this step was performed for RNA extraction, 
far from obtaining higher RNA concentration, we detected 
fragmentation and degradation. Thus, sonication of EVs is 
not appropriate for RNA studies; lysis reagent is efficient 
enough to break EVs membranes. Noteworthy, treatment 
with RNAse A was critical to eliminate the exogenous 
material while preserving the inner genomic content. We 
found that more than half of the RNA isolated from EVs 
preparations was exogenous. This abundant contamina-
tion should be considered, and if possible depleted when 
conducting transcriptomic studies. In line with this, a treat-
ment to clean up EVs membranes from extraneous adhered 
(See figure on previous page.) 
Fig. 3 Optimization of EVs isolation from uterine aspirates for RNA analysis. a Schematic representation of the four conditions tested to isolate EVs 
from uterine aspirates in order to purify their RNA content. Modifications were introduced to the standard protocol of ultracentrifugation. Protocol 
“A”: Sonication prior to RNase A treatment was applied to isolated EVs. Protocol “B”: Sonication of isolated EVs. Protocol “C”: RNase A treatment of 
isolated EVs. Protocol “D”: No modifications were included. b Concentration and quality of RNA derived from each condition was analyzed with an 
Agilent Bioanalyzer. c Ct values of miR‑200b, miR‑200c, miR‑223, miR‑205, miR‑17 and miR‑106a are plotted for each Protocol
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proteins could have been tested. Trypsin is often used to 
break protein interactions; this property could be applied to 
analyze those proteins specifically contained in EVs. How-
ever, considering that the main EVs markers and possibly 
other proteins of interest are transmembrane structures, 
this digestion could affect the extracellular domains com-
promising protein structure, function and interaction with 
other proteins.
A wide range of different uterine specimens collected by 
various procedures is described in the literature [53–57]. 
Concomitant with our observation that female genital tract 
RNAs are detected in EVs from UAs, Vilella et al. proved 
that EVs isolated from endometrial fluids are certainly 
secreted by the endometrial epithelium cells, and conse-
quently, their content may reflect the physiologic state of 
the uterine cavity. Importantly, these findings promote the 
use of EVs in UAs to search for those alterations that may 
originate from anomalous cells in the female genital tract, 
as the same rationale has been performed in other body 
fluids, such as bronchoalveolar lavage fluid of asthmatic 
patients [58] and urine of prostate cancer patients [59].
Conclusions
We confirmed the existence of exosome-like vesicles in the 
fluid fraction of uterine aspirates. They were successfully 
isolated by differential centrifugation giving sufficient pro-
teomic and transcriptomic material for further analyses. 
The Standard protocol was the best performing procedure 
since the other two tested protocols did not ameliorate 
neither yield nor purity of exosome-like vesicles. Certainly, 
our study contributes to standardize protocols and opens 
the door to conduct reliable and reproducible comparative 
studies using EVs isolated from UAs to foster the field of 
biomarker research in gynecology shortly.
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